Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Methods and compositions for treating CD33+ cancers and improving in vivo persistence of chimeric antigen receptor T cells

Methods and compositions for treating CD33+ cancers and improving in vivo persistence of chimeric antigen receptor T cells

US Patent 12053490 · Granted Aug 6, 2024

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Subcutaneous dosing of anti-CD20/anti-CD3 bispecific antibodies2025
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies2025
Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab2025
Antibody buffering of a ligand in vivo2015